Barclays PLC boosted its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Free Report) by 34.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,635 shares of the company’s stock after purchasing an additional 24,602 shares during the quarter. Barclays PLC owned 0.17% of Design Therapeutics worth $520,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. bought a new stake in shares of Design Therapeutics during the second quarter valued at approximately $4,004,000. FMR LLC boosted its stake in Design Therapeutics by 922.8% during the third quarter. FMR LLC now owns 828,665 shares of the company’s stock worth $4,458,000 after buying an additional 747,649 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Design Therapeutics by 61.6% during the third quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock worth $8,612,000 after buying an additional 609,939 shares in the last quarter. Almitas Capital LLC increased its holdings in Design Therapeutics by 22.1% in the 2nd quarter. Almitas Capital LLC now owns 1,253,248 shares of the company’s stock valued at $4,198,000 after buying an additional 227,180 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Design Therapeutics by 44.5% in the 2nd quarter. Acadian Asset Management LLC now owns 583,160 shares of the company’s stock valued at $1,952,000 after buying an additional 179,614 shares in the last quarter. 56.64% of the stock is currently owned by institutional investors and hedge funds.
Design Therapeutics Stock Performance
Shares of Design Therapeutics stock opened at $6.17 on Friday. Design Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $7.77. The firm has a market cap of $349.35 million, a P/E ratio of -7.26 and a beta of 1.86. The firm’s 50-day simple moving average is $6.01 and its 200-day simple moving average is $5.12.
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
- Five stocks we like better than Design Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- How to buy stock: A step-by-step guide for beginnersÂ
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Market Cap Calculator: How to Calculate Market Cap
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Want to see what other hedge funds are holding DSGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Design Therapeutics, Inc. (NASDAQ:DSGN – Free Report).
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.